Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 563-569

  Wang, Yongqing ^a   Zhang, Hongwen ^a   Meng, Ling ^a   Wang, Meifeng ^a   Yuan, Hongyu ^a   Ou, Ning ^a   Zhang, Haibo ^a   Li, Ziyan ^a   Shi, Ruihua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CYP2C19 genotype; Heterozygous extensive metabolizers; Homozygous extensive metabolizers; Omeprazole; Poor metabolizers

Indexed keywords

CYTOCHROME P450 2C19; OMEPRAZOLE; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; PROTON PUMP INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SINGLE DRUG DOSE; STOMACH PH; ASIAN; BLOOD; CHINA; GENETIC POLYMORPHISM; GENETICS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; PH; REFERENCE VALUE; STOMACH;

ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENOTYPE; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; OMEPRAZOLE; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; REFERENCE VALUES; STOMACH;

EID: 77954937837     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0821-6     Document Type: Article

References (23)

1. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958
2. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R (2000) Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119:670-676
3. TsukasaU, TakenoriN,Makoto H,NorioYF,Kazunobu S, Tomonori T (2007) Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations. Eur J Clin Pharmacol 63:143-149
4. Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T (2008) Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Dig Dis Sci 53:933-937
5. Klotz U, Schwab M, Treiber G (2004) CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 95:2-8
6. Niioka T, Uno T, Sugimoto K, Sugawara K, Hayakari M, Tateishi T (2007) Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. Eur J Clin Pharmacol 63:1031-1038
7. Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297-302
8. Hu XP, Xu JM, Hu YM, Mei Q, Xu XH (2007) Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharmacol Ther 32(5):517-524
9. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877-880
10. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH (2006) The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 101:1467-1475
11. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15 (12):1929-1937 (Pubitemid 34014349)
12. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Mol Ther 83:322-327
13. Norio YF, Takenori T, Taku N, Gen Y, Yoshimasa I, Sunao K, Tomonori T (2004) Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 57(4):487-494
14. DSc GS, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K (2007) The gastric H, K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 41:S226-S242
15. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolismin carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65(5):767-774
16. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113
17. Horn J (2004) Relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther 20[Suppl 6]:11-19
18. Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR, Guo YZ (2006) Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol 62:1-6
19. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatr 9:442-473
20. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, Flockhart DA, Illei GG (2004) Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 50:2202-2210
21. Li Y, Hou J, Jiang H, Wang D, Fu W, Yuan Z, Chen Y, Zhou L (2007) Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematol 92:1246-1249
22. Bottiger Y (2006) Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4. Eur J Clin Pharmacol 62:621-625
23. Walton R, Kimber M, Rockett K, Trafford C, Kwiatkowski D, Sirugo G (2005) Haplotype block structure of the cytochrome P450 CYP2C gene cluster on chromosome 10. Nat Genet 37:915-916